How to Help Your Patients Save Money on Voquezna: A Provider's Guide to Savings Programs

Prescribing Voquezna (vonoprazan) is only half the battle. As a gastroenterologist, internist, or primary care physician, you know that if a patient can't afford their medication, it won't be taken — and the clinical outcome won't improve. This guide is for prescribers who want to proactively help their patients navigate Voquezna's cost landscape and access every available savings option.

Understanding the Cost Landscape

Voquezna is brand-name only, with no generic equivalent expected until after 2030. The average retail cash price is approximately $829–$1,013 per 30-day supply. Without assistance, this cost is prohibitive for most patients. However, with the right programs in place, commercially insured patients can typically pay as little as $25/month.

The four main categories of patients you'll encounter, and their best savings pathways:

• Commercially insured: Voquezna Savings Card is the primary resource. Best combined with BlinkRx for PA support and delivery.

• Medicare Part D patients: Savings Card is not available. Focus on formulary coverage, plan exceptions, and the $2,000 Part D out-of-pocket cap. Consider PPI alternatives if cost is prohibitive.

• Medicaid patients: Savings Card not available. Check state Medicaid formulary. Generic PPI alternatives may be more accessible.

• Uninsured/underinsured: GoodRx (~$199) or SingleCare (~$583) can help. No formal PAP is currently available. A PPI alternative may be more appropriate.

The Voquezna Savings Card: Key Details for Prescribers

The Voquezna Savings Card is Phathom Pharmaceuticals' manufacturer copay assistance program. Here are the key facts your practice should know:

• Patient eligibility: U.S. resident, 18+, with commercial insurance that covers Voquezna. NOT eligible if enrolled in Medicare, Medicaid, or any other government-funded program.

• Benefit: As little as $25 per fill for 30, 60, or 90-day supplies of Voquezna tablets (and Triple/Dual Pak).

• Enrollment: Patient enrolls at voquezna.com/savings or calls 1-833-366-7149. BlinkRx can also apply the card automatically for eligible patients.

• Maximum annual savings: Check current terms at voquezna.com/savings — maximums can change by program year.

• Not a patient assistance program: The Savings Card requires commercial insurance coverage — it supplements insurance copays. It does not provide free Voquezna for uninsured patients.

BlinkRx: The Most Efficient Prescription Pathway for Most Patients

For commercially insured patients, e-prescribing to BlinkRx is the single most efficient way to reduce both access barriers and cost burden. BlinkRx:

• Determines coverage and calculates the lowest available out-of-pocket cost

• Automatically applies the Voquezna Savings Card for eligible patients

• Initiates and tracks prior authorization

• Delivers Voquezna to the patient's home

• Provides pharmacist/technician support for adherence questions

To e-prescribe via BlinkRx, search "BlinkRx US Boise, Idaho" in your EMR's pharmacy lookup. Prescriber setup: 1-844-759-0782.

Navigating Insurance: Prior Authorization and Step Therapy

Prior authorization (PA) is required by most commercial and Medicare plans before Voquezna is covered. Step therapy — requiring documented failure of a generic PPI first — is common. Key strategies to support your patients:

• Document PPI failures in the medical record. Include drug names, doses, duration, and reason for failure (e.g., persistent Grade C EE on endoscopy after 8 weeks of esomeprazole 40 mg). This is essential for step therapy and PA approval.

• Submit PA before prescribing. Proactive PA submission reduces the number of patient callbacks about rejected prescriptions.

• Offer peer-to-peer review when denied. If PA is denied, offer to conduct a peer-to-peer review with the plan's medical director. This is often successful for Grade C/D erosive esophagitis with documented PPI failure.

• Use BlinkRx PA support. BlinkRx tracks and initiates PAs, reducing the administrative burden on your practice.

What to Tell Patients at the Point of Prescribing

Your office visit is the best moment to set cost expectations and equip patients to access savings. Consider a brief verbal or written checklist:

1. "Voquezna's sticker price is high, but with your commercial insurance and this savings card, you should pay about $25."

2. "We're routing your prescription through BlinkRx — they'll contact you by text to confirm your cost and arrange delivery."

3. "If you have Medicare, the manufacturer savings card isn't available — let's check your Part D plan's coverage."

4. "If your insurance rejects it, call us — we can start a prior authorization."

When Voquezna Isn't Cost-Effective: PPI Alternatives

For patients who cannot access the Savings Card (Medicare, Medicaid, uninsured) and for whom cost is a primary concern, a high-dose generic PPI may be a more appropriate option — particularly for:

• Mild-to-moderate non-erosive GERD (where PPIs and Voquezna have comparable outcomes)

• LA Grade A/B erosive esophagitis (where healing rates are more similar between agents)

• H. pylori with susceptible (non-resistant) strains, where standard PPI-based triple therapy remains appropriate

Generic omeprazole 40 mg or esomeprazole 40 mg is available for roughly $5–$30/month and may be the most cost-effective option for patients who cannot access Voquezna affordably.

Monitoring for Treatment Success

Once patients have successfully filled their prescription, confirm adherence and response at follow-up. For erosive esophagitis, consider repeat endoscopy after 8 weeks to confirm healing. For H. pylori, test-of-cure (urea breath test or stool antigen, at least 4 weeks after completing treatment and off PPI/Voquezna for 2+ weeks) is recommended to confirm eradication.

The Bottom Line

With the Voquezna Savings Card and BlinkRx, most commercially insured patients can access vonoprazan for $25/month. Proactive documentation, PA submission, and patient education at the point of prescribing dramatically reduce downstream abandonment. For provider resources and to help your patients locate Voquezna in stock, visit medfinder.com/providers.